A Systematic Review on the Role of Βeta-Blockers in Reducing Cardiac Arrhythmias in Long QT Syndrome Subtypes 1-3.

Autor:	Went TR; Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Sultan W; Medicine, Beni Suef University Faculty of Medicine, Beni Suef, EGY.; Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.; Surgery, Halifax Health Medical Center, Daytona Beach, USA., Sapkota A; Psychiatry, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Khurshid H; Medicine and Psychiatry, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Qureshi IA; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Jahan N; Psychiatry, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Tara A; General Medicine, General Surgery, and Emergency Department, Jinnah Postgraduate Medical Centre, Karachi, PAK.; Neurosurgery and General Surgery, Liaquat University of Medical and Health Sciences, Karachi, PAK.; Neurosurgery and General Surgery, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Win M; General Surgery, Nottingham University Hospitals NHS Trust, Nottingham, GBR.; General Surgery, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Wiltshire DA; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Kannan A; Neurological Surgery Research, Surgical Oncology Research, and General Surgery Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.; Surgical Pharmacology, General Surgery, and Surgery, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IND., Ruo SW; General Surgery Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Alfonso M; Medicine, Universidad del Rosario, Bogota, COL.; Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2021 Sep 01; Vol. 13 (9), pp. e17632. Date of Electronic Publication: 2021 Sep 01 (Print Publication: 2021).
DOI:	10.7759/cureus.17632
Abstrakt:	Long QT syndrome (LQTS) is one of the most common inherited cardiac channelopathies with a prevalence of 1:2000. The condition can be congenital or acquired with 15 recognized genotypes; the most common subtypes are LQTS 1, 2, and 3 making up to 85%-90% of the cases. LQTS is characterized by delayed ventricular cardiomyocyte repolarization manifesting on the surface electrocardiogram (EKG) by a prolonged corrected QT (QTc) interval. The mainstay of treatment for this condition involves in part or combination medical therapy via β-blockers as first-line (or other anti-arrhythmic), left cardiac sympathectomy, or implantable cardiac defibrillator placement. Given the high rate of adverse cardiac events (ACE) or sudden cardiac death (SCD) in this population of patients with this disease, this review seeks to highlight the genotype-specific treatment consensus in β-blocker therapy of the most common subtypes. A database search of PubMed, PMC, and Medline was conducted to ascertain the most recent data in the last five years on the management of LQTS types 1-3 and the role of β-blockers in reducing ACE in these types. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were adhered to in the study selection, and selected studies focused on humans, written in the English Language, and within the last five years of LQTS subtypes 1, 2, and 3. Eleven relevant studies were selected after considering inclusion criteria, exclusion criteria, and quality appraisal within the last five years, focusing on β-blocker selection directed based on the subtypes of LQTS. Two meta-analyses, one cohort study, and eight reviews provided significant data that non-selective β-blockers unequivocally are of benefit in these LQTS types. Summary of findings suggested nadolol followed by propranolol yields the best results in LQTS 1, while nadolol would yield the best effect in LQTS 2 and 3. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Went et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu